FDA已正式批准Freenome公司研发的Simplescreen™ CRC血液筛查测试。这款基于血液样本的结直肠癌筛查工具,将被授权给雅培(Abbott)在美国市场进行商业化推广。这一决定标志着非侵入性癌症检测领域迈出了关键一步,为患者提供了更便捷的筛查选择。
FDA已正式批准Freenome公司研发的Simplescreen™ CRC血液筛查测试。这款基于血液样本的结直肠癌筛查工具,将被授权给雅培(Abbott)在美国市场进行商业化推广。这一决定标志着非侵入性癌症检测领域迈出了关键一步,为患者提供了更便捷的筛查选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.